

MARKET REPORT



KOL Perspectives: Cardiovascular safety profile of JAK inhibitors in Rheumatoid Arthritis

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



KOL Perspectives: Cardiovascular safety profile of JAK inhibitors in Rheumatoid Arthritis

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

KOL Perspectives: Cardiovascular safety profile of JAK inhibitors in Rheumatoid Arthritis

KOL Perspectives: Cardiovascular safety profile of JAK inhibitors in Rheumatoid Arthritis

Summary

This KOL Insight briefing focuses on KOL opinions of the safety of JAK inhibitors in rheumatoid arthritis (RA).

The briefing includes analysis of KOL opinion on the following topic areas -

- Baricitinib safety profile with regards to cardiovascular signal
- Tofacitinib safety profile with regards to cardiovascular signal
- Upadacitinib safety profile with regards to cardiovascular signal
- Filgotinib safety profile with regards to cardiovascular signal
- Most favorable JAK inhibitor with regards to cardiovascular safety
- Extent in which thromboembolic events is a class effect across all JAK inhibitors
- Additional studies / actions required to mitigate concerns around cardiovascular safety in the JAK inhibitors class

Key Highlights

- Majority of KOLs acknowledged that there was a CV signal with baricitinib in RA, although many flagged this was not necessarily a concern
- While KOLs generally had a positive opinion of tofacitinib's CV risk profile, many stated the need for more safety data
- Most KOLs highlighted the need for additional data before drawing conclusions regarding upadacitinib's CV safety profile.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our RA key opinion leaders (KOLs)
- In total, we conducted interviews with 10 KOLs: Five Europe-based & five US-based
- Interviews conducted in December 2017
- KOL data is analyzed to produce: Charts summarizing KOL opinions
- Chart call-outs of key information & details

- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "Cardiovascular safety profile of JAK inhibitors in Rheumatoid Arthritis".
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of rheumatoid arthritis
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Additional Details

Publisher : Global Data
Reference : GDHC008SP
Number of Pages : 32
Report Format : PDF
Publisher Information :



GlobalData»

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for KOL Perspectives: Cardiovascular safety profile of JAK inhibitors in Rheumatoid Arthritis [Report Updated: 01-02-2018]

- Table of Contents Executive Summary Background Research Panel Composition Results & Implications Appendix

How to Buy...

KOL Perspectives: Cardiovascular safety profile of JAK inhibitors in Rheumatoid Arthritis [Report Updated: 01-02-2018]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/224122>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$2500** | Single User Price
- \$5000** | Site License Price
- \$7500** | Global License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.